# What will Hims say during their next earnings call?

On May 11, 2026

Updated: May 8, 2026

Category: Mentions

Tags: Earnings

HTML: /markets/mentions/earnings/what-will-hims-say-during-their-next-earnings-call/

## Short Answer

**Key takeaway.** Both the **model** and the **market** expect Peptide to be mentioned during Hims' next earnings call, with no compelling evidence of mispricing.

## Key Claims (January 2026)

**- - FDA appears to have aggressively targeted compounded GLP-1s impacting Hims.** - Peptide-based weight loss is expected as Hims' primary growth driver.
- Hims appears to have shifted its Q1 2026 GLP-1 strategy.
- Hims anticipates a significant Canadian weight loss **market** entry in 2026.
- Hims is set to host its Q1 2026 earnings call on May 11, 2026.
- Management previously guided a Q1 revenue headwind due to shipping shifts.

### Why This Matters (GEO)

- AI agents extract claims, not arguments.
- Improves citation probability in summaries and answer cards.
- Enables fact stitching across multiple sources.

## Executive Verdict

**Key takeaway.** **Model** **probability** of **4.6%** versus 11c **market** implies a 9.1x payout if **model** is correct, given Q1 data inaccessibility.

### Who Wins and Why

| Outcome | Market | Model | Why |
| --- | --- | --- | --- |
| FDA | 56.0% | 61.4% | Regulatory developments or approvals from the FDA are often material to Hims' business operations. |
| Lab Testing | 90.0% | 85.9% | Hims may discuss its diagnostic capabilities or partnerships related to lab testing services. |
| Collaboration | 76.0% | 76.5% | Discussions often include new or ongoing collaborations that impact Hims' strategic growth. |

## Model vs Market

| Outcome | Market Probability | Octagon Model Probability |
| --- | --- | --- |
| FDA | 56.0% | 61.4% |
| Lab Testing | 90.0% | 85.9% |
| Collaboration | 76.0% | 76.5% |
| Canada | 75.0% | 67.3% |
| Testosterone | 90.0% | 86.8% |
| Peptide | 92.0% | 92.0% |
| Zava | 71.0% | 62.2% |
| Vitamin | 74.0% | 66.0% |
| Regulation | 80.0% | 73.7% |
| Tariff | 3.0% | 1.0% |
| Microdose / Microdosing | 20.0% | 10.1% |
| Cancer | 11.0% | 4.6% |
| Amazon | 0.0% | 0.0% |
| Europe | 0.0% | 0.0% |

- Expiration: September 30, 2026

## Market Behavior & Price Dynamics

This market has experienced a sharp upward trend, moving from a starting price of 2.0% to its current level of 11.0%. The entirety of this price movement appears to have occurred between May 7 and May 8, where the perceived probability jumped by 9 percentage points. The provided context, which focuses on the scheduled May 11 earnings call and consensus analyst expectations, does not offer a specific catalyst for this abrupt price increase. The key price points established are the low of 2.0% and the current high of 11.0%, which acts as the current resistance level.

The trading volume in this market is exceptionally low, with a total of only one contract traded. This suggests very limited market participation and conviction behind the price movement. A single trade could be responsible for the significant shift from 2.0% to 11.0%. Due to this thin trading activity, the current price may not be a reliable indicator of broader market sentiment. While the price chart indicates a shift toward a higher perceived probability of the outcome, the lack of volume makes it difficult to assess the strength or validity of this sentiment.

## Significant Price Movements

### Outcome: Regulation

#### 📈 May 08, 2026: 69.0pp spike

Price increased from 11.0% to 80.0%

**What happened:** The primary driver for the reported 69.0 percentage point spike in the "Regulation" outcome on May 08, 2026, related to Hims' next earnings call, cannot be identified from the provided web research [[^]](https://kalshi.com/markets/kxearningsmentionhims/hims-earnings/kxearningsmentionhims-26jun30). The available sources explicitly state that this specific market movement and its associated "social media catalyst" are not corroborated and cannot be tied to a company statement or event with high confidence [[^]](https://kalshi.com/markets/kxearningsmentionhims/hims-earnings/kxearningsmentionhims-26jun30). While there have been ongoing regulatory discussions concerning FDA proposals regarding GLP-1 compounding that impact Hims [[^]](https://www.marketbeat.com/originals/what-the-fdas-latest-proposal-means-for-lilly-novo-and-hims/)[[^]](https://www.investing.com/analysis/what-the-fdas-latest-proposal-means-for-lilly-novo-and-hims-200679902)[[^]](https://www.tikr.com/blog/hims-hers-is-down-7-after-fda-proposes-new-glp-1-drug-rules-heres-what-investors-should-know)[[^]](https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-pressure-tests-hims-and-hers-weight-loss-growth-story), no specific social media activity, traditional news, or announcements from May 08, 2026, that would explain this particular price movement were found. Therefore, social media activity appears irrelevant to this uncorroborated event based on the given information.

### Outcome: FDA

#### 📈 May 07, 2026: 39.0pp spike

Price increased from 51.0% to 90.0%

**What happened:** The primary driver of the prediction market price movement was traditional news and coverage regarding the FDA's proposed rules to curb mass compounding of GLP-1 drugs [[^]](https://www.tikr.com/blog/hims-hers-is-down-7-after-fda-proposes-new-glp-1-drug-rules-heres-what-investors-should-know)[[^]](https://www.marketbeat.com/originals/what-the-fdas-latest-proposal-means-for-lilly-novo-and-hims/). Around May 2026, reports indicated Hims & Hers was expected to address these proposals during its upcoming Q1 2026 earnings call on May 11, 2026, likely arguing that the new rules would not impact its platform due to its sourcing practices and shift towards branded partnerships [[^]](https://www.tikr.com/blog/hims-hers-is-down-7-after-fda-proposes-new-glp-1-drug-rules-heres-what-investors-should-know)[[^]](https://www.marketbeat.com/originals/what-the-fdas-latest-proposal-means-for-lilly-novo-and-hims/)[[^]](https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-pressure-tests-hims-and-hers-weight-loss-growth-story)[[^]](https://investors.hims.com/events-and-presentations/events-calendar/event-details/2026/Hims--Hers-First-Quarter-2026-Earnings-Call/default.aspx)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026/default.aspx). This ongoing regulatory pressure and the anticipation of management's commentary significantly increased the market's expectation for "FDA" to be mentioned. Social media activity was not identified as a factor based on the provided sources.

## Contract Snapshot

The "Collaboration" market resolves to YES if the exact word, or its plural/possessive form, is spoken by any Hims & Hers Health, Inc. representative during their next earnings call (including Q&A); otherwise, it resolves to NO. The market opened on May 7, 2026, and will close upon the outcome or by September 30, 2026, with payouts projected 30 minutes after closing. Resolution primarily uses the earnings call video, with transcripts as a secondary source if a consensus cannot be reached; insider trading is prohibited.

## Market Discussion

Hims & Hers Health (HIMS) is expected to report Q1 2026 earnings on May 11, 2026 [[^]](https://www.marketbeat.com/earnings/reports/2026-5-11-hims-hers-health-inc-stock/), with analysts projecting an EPS of $0.03 and revenue of $616.9M [[^]](https://news.alphastreet.com/hims-hers-health-q1-2026-earnings-preview-may-11-street-expects-0-03-eps/). Prediction markets indicate a 78-85% probability of an earnings beat [[^]](https://www.lines.com/prediction-markets/finance/hims-quarterly-earnings-gaap-eps-05-11-2026-0pt03)[[^]](https://lmsh7.ggff.net/event/hims-quarterly-earnings-gaap-eps-05-11-2026-0pt03). Management is anticipated to provide commentary on key topics, including weight loss subscriber growth, margin performance, regulatory issues surrounding semaglutide compounding, and competition [[^]](https://news.alphastreet.com/hims-hers-health-q1-2026-earnings-preview-may-11-street-expects-0-03-eps/)[[^]](https://medium.com/the-investors-handbook/hims-stock-revenue-up-earnings-down-what-matters-more-c6652d218260).

## Market Data

| Contract | Yes Bid | Yes Ask | Last Price | Volume | Open Interest |
| --- | --- | --- | --- | --- | --- |
| Amazon | 5% | 50% | 0% | $0 | $0 |
| Canada | 66% | 74% | 75% | $215.57 | $193.21 |
| Cancer | 36% | 79% | 11% | $1.11 | $1.11 |
| Collaboration | 67% | 74% | 76% | $300.12 | $291.12 |
| Europe | 33% | 89% | 0% | $0 | $0 |
| FDA | 81% | 95% | 56% | $427.46 | $427.46 |
| Lab Testing | 82% | 90% | 90% | $346.91 | $341.91 |
| Microdose / Microdosing | 3% | 41% | 20% | $10 | $10 |
| Peptide | 84% | 92% | 92% | $163.03 | $151.17 |
| Regulation | 81% | 85% | 80% | $34.13 | $34.13 |
| Tariff | 3% | 46% | 3% | $17.05 | $17.05 |
| Testosterone | 90% | 93% | 90% | $187.43 | $187.43 |
| Vitamin | 38% | 74% | 74% | $34.66 | $30.68 |
| Zava | 72% | 75% | 71% | $86.08 | $81.08 |

## What regulatory actions or FDA commentary regarding compounded drugs in Q1 2026 could force Hims to address the topic on their May 11 earnings call?

FDA Commissioner Statement | February 6, 2026 [[^]](https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs) |
Telehealth Warning Letters | 30 [[^]](http://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s)[[^]](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s) |
Hims-owned Compounder Cited | MedisourceRx [[^]](https://www.statnews.com/pharmalot/2026/02/09/fda-inspection-warns-hims-compounder-bugs-wegovy/) |

**FDA aggressively targeted compounded GLP-1s, directly impacting Hims**

FDA aggressively targeted compounded GLP-1s, directly impacting Hims. On February 6, 2026, FDA Commissioner Martin Makary stated the agency's intent to take "decisive steps" to restrict the use of GLP-1 active pharmaceutical ingredients (APIs) in non–FDA-approved compounded drugs being mass-marketed. The FDA stated it cannot verify the quality, safety, or efficacy of these products and cautioned against claims that they are generic versions, "the same as" FDA-approved drugs, or clinically proven [[^]](https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs). Notably, the FDA explicitly named "Hims & Hers" due to compliance issues with a Hims-owned compounder. A STAT report detailed that MedisourceRx, a compounder associated with Hims, received an FDA warning letter for failing to report a serious adverse event, specifically a patient hospitalization involving a compounded semaglutide product, within the required 15 days. This incident highlights the FDA's readiness to address compliance within Hims' supply chain [[^]](https://www.statnews.com/pharmalot/2026/02/09/fda-inspection-warns-hims-compounder-bugs-wegovy/).

Additional regulatory actions targeted telehealth companies and clarified compounding policies. On March 3, 2026, the FDA issued 30 warning letters to various telehealth companies for making false or misleading claims about compounded GLP-1 products [[^]](http://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s)[[^]](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s). These violations included implying compounded products were identical to FDA-approved drugs and obscuring product sourcing by branding them under the telehealth firm's name without proper qualification [[^]](http://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s)[[^]](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s). An April 1, 2026, policy clarification further reminded compounders that their products must meet specific statutory conditions for 503A/503B exemptions and reinforced restrictions on compounding drugs that are "essentially a copy" of FDA-approved alternatives [[^]](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize).

## What evidence from industry reports and analyst commentary in 2026 supports the idea that peptide-based weight loss is now a primary growth driver for Hims?

Primary Growth Driver | Peptide-based weight loss (2026 industry reports) [[^]](https://www.world-today-news.com/hims-peptides-a-potential-revenue-driver-ahead-of-2026-fda-review/)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx) |
Regulatory Catalyst | FDA regulatory movement on peptides (2026 commentary) [[^]](https://www.tikr.com/blog/novo-deal-eucalyptus-acquisition-fda-peptides-three-catalysts-reshaping-hims-hers-in-2026) |
Addressable Market Potential | Multi-billion-dollar by 2028 (expected from new peptide indications) [[^]](https://www.world-today-news.com/hims-peptides-a-potential-revenue-driver-ahead-of-2026-fda-review/) |

**Peptide-based weight loss emerges as Hims' primary growth driver in 2026**

Peptide-based weight loss emerges as Hims' primary growth driver in 2026. Industry reports indicate that this area is perceived as a "strategic pivot" and a potential "new primary growth narrative" by **market** observers [[^]](https://www.world-today-news.com/hims-peptides-a-potential-revenue-driver-ahead-of-2026-fda-review/)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx). Anticipated FDA regulatory developments concerning peptides are seen as a key catalyst for the company's future growth [[^]](https://www.tikr.com/blog/novo-deal-eucalyptus-acquisition-fda-peptides-three-catalysts-reshaping-hims-hers-in-2026). For instance, a TIKR report mentioned an April 16 FDA expert panel on 12 peptides, with Leerink suggesting this could enable Hims to utilize its existing peptide facility as demand for compounded weight-loss treatments evolves [[^]](https://www.tikr.com/blog/novo-deal-eucalyptus-acquisition-fda-peptides-three-catalysts-reshaping-hims-hers-in-2026). World Today News further noted that Q1 2026 call data indicated that peptide-related regulatory changes could open a multi-billion-dollar addressable **market** by 2028 [[^]](https://www.world-today-news.com/hims-peptides-a-potential-revenue-driver-ahead-of-2026-fda-review/).

Hims management prioritizes peptide durability and new weight-loss strategies. The company is strategically positioning its weight-loss business to maintain durability, even if GLP-1 compounding faces restrictions [[^]](https://www.statnews.com/2026/02/23/him-hers-earnings-2026-outlook-compounded-semaglutide/). According to STAT's February 2026 earnings-call coverage, CEO Andrew Dudum emphasized a "really durable weight business," signaling a potential future focus on other weight-loss-peptide initiatives [[^]](https://www.statnews.com/2026/02/23/him-hers-earnings-2026-outlook-compounded-semaglutide/). A March 2026 investor update by Hims detailed a shift in its U.S. weight-loss strategy with Novo Nordisk, leading analysts to anticipate future growth from an approved GLP-1 mix along with new treatment options, potentially including peptide-based offerings [[^]](https://www.fool.com/earnings/call-transcripts/2026/02/23/hims-hers-hims-earnings-call-transcript/). **Market** expectations for the May 11, 2026 call frame it as a crucial "first real test" of the recent Hims rally, scrutinizing management's narrative around the Novo Nordisk partnership and the peptide pipeline [[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx)[[^]](https://finance.yahoo.com/markets/stocks/articles/hims-hers-rallies-9-investors-144053315.html)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026/default.aspx).

## How does Hims' Q1 2026 strategy for GLP-1 and compounded weight loss drugs compare to the offerings of competitors like Amazon Pharmacy and Ro?

Hims GLP-1 Strategy Shift | Collaboration with Novo Nordisk announced March 2026, shifting towards FDA-approved medications [[^]](https://seekingalpha.com/article/4897371-hims-and-hers-novo-nordisk-fda-glp-1-compounding-ruling-may-actually-favor-hims)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx)[[^]](https://investors.hims.com/news/news-details/2026/Novo-Nordisks-FDA-Approved-GLP-1s-Now-Available-With-Hims--Hers/default.aspx)[[^]](https://www.zacks.com/stock/news/2918389/can-platform-expansion-support-hims-hers-stock-before-q1-earnings) |
Ro Compounded GLP-1 Status | Discontinued compounded GLP-1s in early 2026, now solely FDA-approved options [[^]](https://dosemate.com/resources/online-weight-loss-programs-guide) |
Amazon Pharmacy Focus | Consistently focuses on FDA-approved GLP-1 medications, integrating primary and virtual care [[^]](https://www.aboutamazon.com/news/retail/amazon-glp1-management-program)[[^]](https://www.inc.com/leila-sheridan/amazon-glp-1-program/91334186)[[^]](https://www.healthcaredive.com/news/amazon-one-medical-glp-1-management-program/818184/) |

**Hims dramatically shifted its GLP-1 strategy toward FDA-approved medications in Q1 2026, aligning with competitors like Amazon Pharmacy and Ro**

Hims dramatically shifted its GLP-1 strategy toward FDA-approved medications in Q1 2026, aligning with competitors like Amazon Pharmacy and Ro. This pivot was underscored by a March 2026 collaboration with Novo Nordisk, enabling Hims to offer brand-name Ozempic and Wegovy, available in both injectable and oral forms, through its platform [[^]](https://seekingalpha.com/article/4897371-hims-and-hers-novo-nordisk-fda-glp-1-compounding-ruling-may-actually-favor-hims)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx)[[^]](https://investors.hims.com/news/news-details/2026/Novo-Nordisks-FDA-Approved-GLP-1s-Now-Available-With-Hims--Hers/default.aspx)[[^]](https://www.zacks.com/stock/news/2918389/can-platform-expansion-support-hims-hers-stock-before-q1-earnings). As part of this change, Hims announced it would cease advertising compounded GLP-1 offerings and support existing patients in transitioning to FDA-approved medicines when clinically appropriate. While primarily focusing on FDA-approved options, compounded GLP-1s will remain available on a limited basis for patients with specific clinical needs and medical approval from a provider [[^]](https://seekingalpha.com/article/4897371-hims-and-hers-novo-nordisk-fda-glp-1-compounding-ruling-may-actually-favor-hims)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx)[[^]](https://investors.hims.com/news/news-details/2026/Novo-Nordisks-FDA-Approved-GLP-1s-Now-Available-With-Hims--Hers/default.aspx). This strategic move is timely given the FDA's proposed restrictions on compounded GLP-1 drugs, and Hims is also expanding its services into other health areas such as hormone therapy and diagnostics [[^]](https://www.marketbeat.com/originals/hims-and-hers-earnings-preview-the-novo-nordisk-shift-puts-glp-1-strategy-in-focus/)[[^]](https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-pressure-tests-hims-and-hers-weight-loss-growth-story)[[^]](https://dosemate.com/resources/online-weight-loss-programs-guide)[[^]](https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-amazon-ozempic-glp1-ahead-of-earnings/cZX23LbReQx)[[^]](https://www.zacks.com/stock/news/2918389/can-platform-expansion-support-hims-hers-stock-before-q1-earnings).

Competitors like Amazon Pharmacy and Ro primarily offer FDA-approved GLP-1 medications, each with distinct program features. Amazon Pharmacy consistently focuses on FDA-approved weight management solutions, providing both oral options like Wegovy and Foundayo, alongside injectables such as Wegovy, Zepbound, and KwikPen [[^]](https://www.aboutamazon.com/news/retail/amazon-glp1-management-program)[[^]](https://www.inc.com/leila-sheridan/amazon-glp-1-program/91334186)[[^]](https://www.healthcaredive.com/news/amazon-one-medical-glp-1-management-program/818184/). Their program adopts a holistic approach, integrating primary care, Amazon Pharmacy services, and virtual care to manage obesity as a chronic condition, emphasizing convenience with nationwide and same-day delivery options in many cities, as well as transparent pricing that automatically applies manufacturer coupons [[^]](https://www.aboutamazon.com/news/retail/amazon-glp1-management-program)[[^]](https://www.inc.com/leila-sheridan/amazon-glp-1-program/91334186)[[^]](https://www.healthcaredive.com/news/amazon-one-medical-glp-1-management-program/818184/). Similarly, Ro's "Ro Body Program" offers telehealth services with access to prescription FDA-approved GLP-1 medications, including Wegovy, Ozempic, Zepbound, and Saxenda [[^]](https://www.healthline.com/nutrition/ro-review)[[^]](https://www.forhers.com/blog/hers-weight-loss-vs-ro)[[^]](https://ro.co/weight-loss/weight-loss-medication/). Ro specifically ceased selling compounded GLP-1s in early 2026, now exclusively providing FDA-approved options and matching manufacturer pricing for cash-paying customers [[^]](https://dosemate.com/resources/online-weight-loss-programs-guide). A notable aspect of Ro's program is its "insurance concierge" service, designed to help patients navigate insurance coverage, prior authorizations, and appeals for GLP-1 medications. The program also includes a membership fee, one-on-one personal coaching, and educational resources [[^]](https://ro.co/weight-loss/glp-1/)[[^]](https://ro.co/weight-loss/pricing/)[[^]](https://dosemate.com/resources/online-weight-loss-programs-guide).

## What publicly available data tracks prescription volumes for key Hims telehealth categories like peptides and lab testing for the Q1 2026 period?

Hims Q1 2026 Earnings Release Date | Monday, May 11, 2026 [[^]](https://www.businesswire.com/news/home/20260413335848/en/Hims-Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026)[[^]](https://www.marketscreener.com/news/hims-hers-to-announce-first-quarter-2026-financial-results-on-may-11-2026-ce7e50dedc81f525)[[^]](https://www.marketbeat.com/stocks/NYSE/HIMS/earnings/)[[^]](https://earningswhispers.com/newsarticle/HIMS/2604135848) |
FormBlends Peptides Report Release | April 2026 [[^]](https://www.globenewswire.com/news-release/2026/04/28/3282465/0/en/formblends-publishes-2026-state-of-peptides-report-as-rfk-era-hhs-signals-major-shifts-for-glp-1-and-peptide-therapy-access-in-the-united-states.html) |
Telemedicine Flexibilities Extension | December 31, 2026 [[^]](https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html)[[^]](https://www.rstreet.org/commentary/the-state-of-telehealth-policy-january-2026/) |

**Publicly available data explicitly detailing prescription volumes for Hims' key telehealth categories, such as peptides and lab testing, for the first quarter of 2026 is not currently accessible**

Publicly available data explicitly detailing prescription volumes for Hims' key telehealth categories, such as peptides and lab testing, for the first quarter of 2026 is not currently accessible. Hims & Hers Health, Inc. plans to release its first-quarter 2026 financial results after the **market** closes on Monday, May 11, 2026. This announcement will serve as the primary source for detailed company-specific information, and the company will also host a live conference call to discuss these results [[^]](https://www.businesswire.com/news/home/20260413335848/en/Hims-Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026)[[^]](https://www.marketscreener.com/news/hims-hers-to-announce-first-quarter-2026-financial-results-on-may-11-2026-ce7e50dedc81f525)[[^]](https://www.marketbeat.com/stocks/NYSE/HIMS/earnings/)[[^]](https://earningswhispers.com/newsarticle/HIMS/2604135848).

Broader telehealth reports and regulatory changes impact the **market** landscape. A "2026 State of Peptides and GLP-1 Regulation report" was released in April 2026 by FormBlends, a telehealth platform specializing in GLP-1 therapy and peptide research, though the report does not specify if it tracks Q1 2026 prescription volumes [[^]](https://www.globenewswire.com/news-release/2026/04/28/3282465/0/en/formblends-publishes-2026-state-of-peptides-report-as-rfk-era-hhs-signals-major-shifts-for-glp-1-and-peptide-therapy-access-in-the-united-states.html). Further, the FDA is expected to review certain peptides for potential compounding access in July 2026 [[^]](https://pitchbook.com/news/articles/the-fdas-u-turn-on-peptides-could-boost-the-next-telehealth-boom)[[^]](https://openloophealth.com/blog/digital-health-trends-news-may-2026). Telemedicine flexibilities for prescribing controlled medications have also been extended by the HHS and DEA through December 31, 2026 [[^]](https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html)[[^]](https://www.rstreet.org/commentary/the-state-of-telehealth-policy-january-2026/).

## Which potential Q1 2026 milestones in its European or Canadian operations would be significant enough for Hims to highlight during the earnings call?

Canada Generic Semaglutide Patent Expiry | January 2026 [[^]](https://investors.hims.com/news/news-details/2025/Hims--Hers-Announces-Planned-2026-Expansion-to-Canada-Following-ZAVA-Acquisition-Completion/default.aspx)[[^]](https://www.globeandmail.com/business/economy/article-hims-hers-launches-in-canada-in-anticipation-of-generic-ozempic/)[[^]](https://www.proactiveinvestors.com/companies/news/1074436/hims-hers-to-offer-generic-semaglutide-in-canada-starting-in-2026-1074436.html) |
Hims Canada Weight Loss Launch | Planned for 2026, mid-2026 availability [[^]](https://investors.hims.com/news/news-details/2025/Hims--Hers-Announces-Planned-2026-Expansion-to-Canada-Following-ZAVA-Acquisition-Completion/default.aspx)[[^]](https://www.globeandmail.com/business/economy/article-hims-hers-launches-in-canada-in-anticipation-of-generic-ozempic/)[[^]](https://www.proactiveinvestors.com/companies/news/1074436/hims-hers-to-offer-generic-semaglutide-in-canada-starting-in-2026-1074436.html) |
2025 Rest of World Revenue | $134M (399% YoY increase) [[^]](http://web.theglobeandmail.com/investing/markets/stocks/HIMS/pressreleases/376033/hims-hers-hims-earnings-call-transcript/)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm) |

**Hims anticipates a significant Canadian weight loss market entry in 2026**

Hims anticipates a significant Canadian weight loss **market** entry in 2026. This expansion is closely tied to the generic semaglutide patent expiry in January 2026, a crucial factor for its planned weight loss launch. While the patent expires early in the year, the availability of generic semaglutide is projected for mid-2026 [[^]](https://investors.hims.com/news/news-details/2025/Hims--Hers-Announces-Planned-2026-Expansion-to-Canada-Following-ZAVA-Acquisition-Completion/default.aspx)[[^]](https://www.globeandmail.com/business/economy/article-hims-hers-launches-in-canada-in-anticipation-of-generic-ozempic/)[[^]](https://www.proactiveinvestors.com/companies/news/1074436/hims-hers-to-offer-generic-semaglutide-in-canada-starting-in-2026-1074436.html). Hims' entry into the Canadian **market** was made possible by the Livewell acquisition, finalized in December 2025 [[^]](https://news.hims.com/newsroom/hims-hers-continues-major-international-expansion-with-official-entry-into-canada).

No specific European Q1 2026 milestones are highlighted by research. The company's European operations, which cover the UK, Germany, France, and Ireland, were established through the ZAVA acquisition in the second half of 2025 [[^]](https://news.hims.com/newsroom/going-global-expanding-hims-hers-in-europe)[[^]](https://www.nasdaq.com/press-release/hims-hers-announces-plans-acquire-zava-accelerating-major-european-growth-across-uk)[[^]](https://investors.hims.com/news/news-details/2025/Hims--Hers-Announces-Plans-to-Acquire-ZAVA-Accelerating-Major-European-Growth-Across-the-UK-Germany-France-and-Ireland/default.aspx). International operations are identified as a growth driver, contributing to the 2025 Rest of World revenue of **$134** million, reflecting a substantial **399%** year-over-year increase [[^]](http://web.theglobeandmail.com/investing/markets/stocks/HIMS/pressreleases/376033/hims-hers-hims-earnings-call-transcript/)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm). The upcoming Q1 2026 report will mark the first time a comprehensive US versus Rest of World revenue split is included [[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm).

## What Could Change the Odds

**Hims & Hers will host its First Quarter 2026 earnings call on May 11, 2026, at 5:00 p.m.** ET, following the release of Q1 results after the **market** closes the same day [[^]](https://investors.hims.com/events-and-presentations/events-calendar/event-details/2026/Hims--Hers-First-Quarter-2026-Earnings-Call/default.aspx)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026/default.aspx). Management previously guided for an approximately **$65** million first-quarter revenue headwind, attributable to a shift in weight-loss shipping cadences to 503A fulfillment [[^]](https://www.marketbeat.com/earnings/reports/2026-2-23-hims-hers-health-inc-stock/). Additionally, the company expects further EBITDA pressure related to its planned 60-second Super Bowl commercial investment [[^]](https://www.marketbeat.com/earnings/reports/2026-2-23-hims-hers-health-inc-stock/).

**Street expectations for the May 11, 2026 Q1 2026 release include a consensus EPS of $0.03 and revenue of $616.9M [[^]](https://news.alphastreet.com/hims-hers-health-q1-2026-earnings-preview-may-11-street-expects-0-03-eps/).** This outlook comes with a wide EPS range (loss of **$0.04** to **$0.15**) and has seen downward revisions over the prior three months [[^]](https://news.alphastreet.com/hims-hers-health-q1-2026-earnings-preview-may-11-street-expects-0-03-eps/). Polymarket’s "Will Hims & Hers Health (HIMS) beat quarterly earnings?" **market**, set to resolve on or around May 11, 2026, showed a crowd-sourced **probability** of **49%** for "Yes" at the time captured by the source [[^]](https://polymarket.com/event/hims-quarterly-earnings-gaap-eps-05-11-2026-0pt03). A separate prediction-**market** article claims a **market** **probability** of **85.5%** for a beat for the May 11, 2026 resolution, though this appears as secondary commentary [[^]](https://www.lines.com/prediction-markets/finance/hims-quarterly-earnings-gaap-eps-05-11-2026-0pt03).

## Key Dates & Catalysts

- **Expiration:** September 30, 2026
- **Closes:** September 30, 2026

## Decision-Flipping Events

- Hims & Hers will host its First Quarter 2026 earnings call on May 11, 2026, at 5:00 p.m.
- ET, following the release of Q1 results after the **market** closes the same day [^] [^] .
- Management previously guided for an approximately **$65** million first-quarter revenue headwind, attributable to a shift in weight-loss shipping cadences to 503A fulfillment [^] .
- Additionally, the company expects further EBITDA pressure related to its planned 60-second Super Bowl commercial investment [^] .

## Related Research Reports

- [What will Bernie say during his NYC Rally?](/markets/mentions/politicians/what-will-bernie-say-during-his-nyc-rally/)
- [What will Bernie say during his Durham rally?](/markets/mentions/politicians/what-will-bernie-say-during-his-durham-rally/)
- [What will Candace Owens say during her livestream?](/markets/mentions/politicians/what-will-candace-owens-say-during-her-livestream/)
- [What will Drake say in Iceman?](/markets/mentions/politicians/what-will-drake-say-in-iceman/)

## Historical Resolutions

No historical resolution data available for this series.

## Disclaimer

This content is for informational and educational purposes only and does not constitute financial, investment, legal, or trading advice.
Prediction markets involve risk of loss. Past performance does not guarantee future results.
We are not affiliated with Kalshi or any prediction market platform. Market data may be delayed or incomplete.

### Data Sources & Model Transparency

**Data Sources:** Octagon Deep Research aggregates information from multiple sources including news, filings, and market data.

**Freshness:** Analysis is generated periodically and may not reflect the latest developments. Verify critical information from primary sources.

## Attribution Policy

When quoting, summarizing, or reproducing Octagon AI content, attribute it to Octagon AI and link to the Octagon source URL: https://octagonai.co/markets/mentions/earnings/what-will-hims-say-during-their-next-earnings-call
If a specific page was used, cite that page rather than only the site homepage.